Core Viewpoint - The company, Yibo Technology (301366.SZ), has recently received the "High-tech Enterprise Certificate" from the Shenzhen Municipal Bureau of Industry and Information Technology, Shenzhen Municipal Finance Bureau, and the National Taxation Bureau of Shenzhen [1] Group 1 - The recognition of the high-tech enterprise is a re-certification following the expiration of the previous certificate [1] - As a qualified high-tech enterprise, the company will benefit from a corporate income tax rate of 15% for three years starting from the year of recognition, in accordance with national tax incentive policies [1]

Group 1 - The company expects a positive net profit for the fiscal year 2025, but anticipates a decline of over 50% compared to the previous year [3][4] - The performance forecast period is from January 1, 2025, to December 31, 2025 [2] - The company has communicated with its accounting firm regarding the performance forecast, and there are no significant disagreements [3] Group 2 - The increase in losses is attributed to several factors, including the trial production of new PCB and PCBA factories, which have not yet achieved effective capacity release, resulting in an additional loss of approximately 42 million yuan [4] - Currency exchange losses due to the appreciation of the RMB compared to the USD and JPY have increased by nearly 4.5 million yuan [4] - Non-recurring gains and losses, including government subsidies and structured deposit income, are expected to decrease by nearly 8 million yuan compared to the previous year [5] Group 3 - The specific financial data for the fiscal year 2025 will be disclosed in the annual report, which has not yet been audited [6][8]

Group 1 - The company Yibo Technology (301366.SZ) has disclosed its performance forecast for the year 2025, expecting a net profit attributable to shareholders of between 27 million and 35 million yuan, representing a year-on-year decline of 60.49% to 69.52% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 15 million and 20 million yuan, indicating a year-on-year decrease of 70.67% to 78% [1]

Financial Performance Expectations - The company expects a net profit of between 27 million and 35 million CNY for 2025, representing a decline of 60.49% to 69.52% compared to the same period last year[5]. - The net profit after deducting non-recurring gains and losses is projected to be between 15 million and 20 million CNY, reflecting a decrease of 70.67% to 78.00% year-on-year[5]. Losses and Impairments - The company incurred an additional loss of approximately 42 million CNY due to the underperformance of the newly established PCB factory in Zhuhai, which began trial production in Q4 2024[7]. - The new PCBA factory in Tianjin, which started trial production in H2 2024, also contributed to an increased loss of around 4 million CNY[8]. - The company recorded an increase of nearly 2.5 million CNY in provisions for inventory impairment and receivables compared to 2024[8]. Currency and Non-Recurring Items - Currency exchange losses increased by nearly 4.5 million CNY due to the appreciation of the RMB compared to the USD and JPY[7]. - Non-recurring gains and losses, including government subsidies and structured deposit income, decreased by approximately 8 million CNY compared to the previous year[8]. Future Reporting - The financial data for 2025 will be detailed in the annual report, which is yet to be audited[9].

Group 1 - Tianqi Co., Ltd. has entered the brain-computer interface (BCI) sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, achieving animal testing stages, and becoming a key player in domestic BCI hardware localization. The developed flexible neural electrode has 1024 channels, with signal acquisition precision and anti-interference capabilities at an internationally advanced level. The company has also completed biocompatibility surface modification technology to reduce inflammation after electrode implantation, with core patents authorized by the National Intellectual Property Administration [1][2][3] - Innovation Medical, through its subsidiary Boling Brain Machine, is one of the first companies in China to commercialize BCI rehabilitation products. The core product, Cyberlink AC5, was officially launched in October 2025, generating sales revenue of 114,000 yuan in 2025. Another product, Cyberlink AM5, has completed multi-center clinical trials and is progressing through the approval process. The company plans to establish five additional clinical cooperation centers to accelerate the application of BCI technology in treating neurological diseases [4][5][6] - iFlytek is a leading company in the non-invasive BCI field, leveraging its artificial intelligence technology to develop BCI collaborative technology. The company has established long-term partnerships with universities for research and development. Its non-invasive BCI system has been piloted in 120 schools nationwide, improving student attention by 30%. In the medical field, a collaboration with Beijing Tiantan Hospital has achieved a 92% accuracy rate in identifying abnormal brain signals for epilepsy [7][8][9] Group 2 - Jiahe Intelligent focuses on the research and mass production of BCI hardware, particularly EEG acquisition devices and core components, serving both consumer and medical-grade markets. The company has achieved large-scale production of EEG acquisition headphones with a signal recognition accuracy of 92%, primarily used in sleep monitoring and attention training. It plans to expand into overseas BCI hardware markets by 2026 [10][11][12] - Tom Cat is the first company in China to apply BCI technology in consumer scenarios, focusing on interactive games and rehabilitation training products. The company launched a mind-controlled game product in 2025, which quickly gained over 500,000 users. It also collaborates with rehabilitation institutions to develop BCI rehabilitation training systems, showing a 35% average improvement in patient motor function scores [13][14][15] - Hanwei Technology, through its subsidiary Weisheng Technology, is a leading company in the EEG sensor field, with an annual shipment of over 2 million units. The company has developed an epilepsy early warning system with an 88% accuracy rate in clinical tests. It also focuses on flexible pressure sensors for invasive BCI electrodes, addressing industry pain points [16][17][18] Group 3 - StarNet Ruijie leverages its network communication technology to develop low-power, high-stability EEG signal transmission systems and data encryption modules, becoming a core supplier for BCI data links. The developed transmission system supports real-time transmission of 1024-channel EEG signals with a latency of less than 10ms and a stability of 99.9% [19][20][21] - Yijiahe focuses on the integration of BCI and embodied intelligent robots, exploring applications in smart healthcare. The company has signed a strategic cooperation agreement to develop real-time emotional companionship and brain-controlled robots, enhancing the emotional care capabilities of robots [22][23][24] - Lihua Technology is focused on incubating and investing in the BCI sector, successfully incubating three high-tech companies in the field. The company collaborates with the Shenzhen Institute of Advanced Technology to provide comprehensive services for incubated companies, addressing development pain points [25][26][27] Group 4 - Sanbo Neurosurgery is a leading private hospital in the neurosurgery field, focusing on the clinical application and research of BCI. The company has successfully conducted an interventional BCI surgery, accumulating valuable experience for clinical applications. It is also recruiting participants for ongoing clinical trials [28][29][30] - Shiyun Circuit is a core enterprise in the PCB field, providing customized PCB products for BCI devices. The company focuses on high-density, flexible PCB designs, achieving low signal loss rates below 2% [31][32][33] - Meihua Medical is a leading supplier of core components for BCI, having entered the core supply chain for invasive BCI products. The company has developed components that have passed biocompatibility tests, ensuring long-term stability and safety for implanted devices [34][35][36]

Group 1 - The company is currently focused on PCB research and design, as well as PCB and PCBA development, prototyping, and small to medium batch manufacturing services [1] - The company aims to create a one-stop hardware innovation platform that includes PCB design, board manufacturing, component supply, PCBA assembly, and functional testing to meet diverse customer needs [1] - The company plans to deepen collaboration with customers and actively integrate into their R&D and supply chain systems to enhance cooperation and broaden business opportunities, aiming to secure more bulk orders and deliver satisfactory returns to investors [1]

Group 1 - The core viewpoint of the article is that Yibo Technology, as a leader in the PCB R&D service segment, is committed to addressing customer R&D pain points and providing effective one-stop hardware innovation services [1] - As of now, the Zhuhai PCB factory has achieved a maximum delivery capability of 58 layers for customers, with ongoing projects reaching a maximum of 80 layers and a trial production capacity of 120 layers [1]

Core Viewpoint - The company, Yibo Technology, is a leader in the PCB R&D service sector and is focused on addressing customer R&D pain points by providing effective hardware innovation and one-stop services [2]. Group 1: Production Capabilities - The PCB factory in Zhuhai has achieved a maximum delivery capability of 58-layer boards to customers [2]. - Ongoing research projects have reached a maximum layer count of 80 layers, indicating advanced development efforts [2]. - The factory has a trial production capacity of up to 120 layers, showcasing its potential for future production [2].

融券方面，一博科技1月26日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量100.00股，融券余额3805.00元，超过近一年60%分位水平，处于较高位。 分红方面，一博科技A股上市后累计派现1.78亿元。近三年，累计派现1.38亿元。 1月26日，一博科技跌1.25%，成交额1.83亿元。两融数据显示，当日一博科技获融资买入额1531.16万 元，融资偿还1759.03万元，融资净买入-227.87万元。截至1月26日，一博科技融资融券余额合计2.37亿 元。 资料显示，深圳市一博科技股份有限公司位于广东省深圳市南山区粤海街道深大社区深南大道9819号地 铁金融科技大厦11F，成立日期2003年3月24日，上市日期2022年9月26日，公司主营业务涉及以印制电 路板（PCB）设计服务为基础，同时提供印制电路板装配（PCBA）制造服务的一站式硬件创新服务 商。主营业务收入构成为：PCBA制造服务81.02%，PCB设计服务18.51%，其他0.47%。 融资方面，一博科技当日融资买入1531.16万元。当前融资余额2.37亿元，占流通市值的8.15%，融资余 额低于近 ...

Group 1 - The core viewpoint of the article is that Yibo Technology (301366) focuses on providing high-speed PCB R&D design services and small-batch manufacturing services for PCBs and PCBA, aiming to create a one-stop hardware innovation platform to meet diverse customer needs [1] - The company offers a comprehensive range of services including PCB design, board manufacturing, component supply, PCBA welding assembly, and performance testing [1] - Yibo Technology serves a large customer base annually, with specific business developments available through the company's disclosed information and interactive responses [1]